Home / Business and Economy / RenovoRx Surges Past Q2 Targets

RenovoRx Surges Past Q2 Targets

14 Aug

Summary

RenovoRx achieved record revenue in the second quarter, exceeding all previous quarters.
Commercial cancer centers were activated at a faster pace than initially projected.
RenovaCath therapy was used for a non-pancreatic solid tumor for the first time.

RenovoRx announced on Wednesday, August 12, 2026, that it achieved a record revenue quarter for its second quarter. This financial performance marks the strongest to date for the company. Management highlighted the successful activation of new commercial cancer centers, which occurred at a pace exceeding internal projections.

Furthermore, RenovoRx reported a significant clinical milestone. For the first time, a physician utilized RenovaCath to deliver therapy to a patient with a solid tumor other than locally advanced pancreatic cancer. This expansion signifies a critical step in broadening the application of their treatment.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.